Global prevalence and correlates of diabetes distress in type 1 diabetes: A systematic review and meta-analysis.

Diabetes Res Clin PractJul 22, 2026 (epub)
Clinical ResearchEndocrinology

Eric Peprah Osei, Emmanuel Ekpor, Samuel Akyirem et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the prevalence of diabetes distress (DD) in type 1 diabetes (T1D) across 72 studies. The pooled prevalence of elevated DD was found to be 38.9% (95% CI: 33.6-44.5), with higher rates in females. The study highlights the significant associations between DD and various clinical and psychological outcomes.

Key findings

  • The pooled prevalence of elevated diabetes distress in T1D was 38.9% (95% CI: 33.6-44.5).
  • Diabetes distress was positively correlated with HbA1c (r = 0.24) and anxiety (r = 0.42).
  • A strong correlation was found between diabetes distress and depressive symptoms (r = 0.60) and fear of hypoglycemia (r = 0.60).
  • Diabetes distress negatively correlated with self-efficacy (r = -0.58) and quality of life (r = -0.35).

Why it matters

Understanding the prevalence and correlates of diabetes distress in T1D is crucial for clinicians, as it can significantly impact patients' clinical outcomes and overall well-being. Integrating psychosocial assessments into routine care may enhance management strategies.

Source

PubMed · PMID 42486409

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.